MacroGenics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.About MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.
CEOEric Risser
CEOEric Risser
Employees341
Employees341
HeadquartersRockville, Maryland
HeadquartersRockville, Maryland
Founded2000
Founded2000
Employees341
Employees341
MGNX Key Statistics
Market cap86.28M
Market cap86.28M
Price-Earnings ratio-2.37
Price-Earnings ratio-2.37
Dividend yield—
Dividend yield—
Average volume735.17K
Average volume735.17K
High today$1.37
High today$1.37
Low today$1.30
Low today$1.30
Open price$1.36
Open price$1.36
Volume525.64K
Volume525.64K
52 Week high$4.87
52 Week high$4.87
52 Week low$0.9897
52 Week low$0.9897
Stock Snapshot
MacroGenics(MGNX) stock is priced at $1.37, giving the company a market capitalization of 86.28M. It carries a P/E multiple of -2.37.
During the trading session on 2025-11-07, MacroGenics(MGNX) shares reached a daily high of $1.37 and a low of $1.30. At a current price of $1.37, the stock is +5.8% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 525.64K, compared to an average daily volume of 735.17K.
Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $4.87 and a low of $0.99.
Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $4.87 and a low of $0.99.
Analyst ratings
71%
of 7 ratingsBuy
28.6%
Hold
71.4%
Sell
0%
People also own
Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.